Zhengzhou University
Zhengzhou | China


Dr. Mengzhou Xue is a professor, doctoral supervisor at the Second Affiliated Hospital of Zhengzhou University in Zhengzhou, China. He obtained his Ph.D. in University of Manitoba, Canada, and completed post-doctoral training at the University of Calgary in Canada. Dr. Xue’s research is internationally recognized for his contributions to mechanisms and therapy of intracerebral hemorrhage, especially the neuroinflammation in the brain injuries after intracerebral hemorrhage, and the connections among microglia/macrophage, neutrophil, extracellular matrix metalloproteinase inducer and matrix metalloproteinase 9. Dr. Xue has published more than 160 peer-review scientific research articles in prestigious journals such as Lancet Neurol (IF:59.935), Brain (IF:15.255), and Stroke (IF:10.170). He has presided over 1 Key Project of International Cooperation and Exchanges, 3 General Program of the National Natural Science Foundation of China, 1 National Key Research and Development Program of China and multiple provincial projects since 2014. The research fund is more than 20 million RMB. Dr. Xue has earned numerous awards and distinctions, including expert obtaining Special Government Allowances of the State Council; review member for National Natural Science Foundation of China, the Ministry of Science and Technology Major Projects and National Key Research and Development Program; “Changjiang Scholars Program of China” and Key Laboratory; vice director of Chinese Medical Doctor Association Stroke Neuronal Repair Committee; vice director of Chinese Stroke Society Intracerebral Hemorrhage Minimally Invasive Treatment Branch; etc. Dr. Xue also serves as an associate editor and editorial board member of 8 international journals.


Selected publications (5 of 161)

  1. Xue M, Yong VW*. Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation. Lancet Neurol. 2020. DOI: 1016/S1474-4422(20)30364-1. (IF=48.0)
  2. Bai Q, Xue M*, Yong VW*. Microglia and macrophage phenotypes in intracerebral haemorrhage injury: therapeutic opportunities. Brain. 2020. DOI: 10.1093/brain/awz393. (IF=14.5)
  3. Zhang R, Wuerch E, Wee Yong V*, Xue M*. LXR agonism for CNS diseases: promises and challenges. Journal of Neuroinflammation. 2024. doi: 10.1186/s12974-024-03056-0. (IF=9.8)
  4. Khan S; Siddique R; Liu Y; Wee Yong V*; Xue M*. Towards improving the prognosis of stroke through targeting the circadian clock system. International Journal of Biological Sciences. 2024; 20(2): 403-413. doi: 10.7150/ijbs.88370. (IF=9.2)
  5. Zhang X, Khan S, Wei R, Zhang Y, Liu Y, Wee Yong V*, Xue M*. Application of nanomaterials in the treatment of intracerebral hemorrhage. Journal of Tissue Engineering. 2023;14:20417314231157004. doi:10.1177/20417314231157004. (IF= 8.2)
  6. Zhang R, Dong Y, Liu Y, Moezzi D, Ghorbani S, Mirzaei R, Lozinski BM, Dunn JF, Yong VW*, Xue M*. Enhanced liver X receptor signaling reduces brain injury and promotes tissue regeneration following experimental intracerebral hemorrhage: roles of microglia/macrophages. Stroke and Vascular Neurology 2023;8(6):486-502. doi:10.1136/svn-2023-002331. (IF=5.9)